BOSTON--(Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, announced that Mr. Eamonn Hobbs has assumed the role of Chairman of the Board of Directors, effective immediately. Mr. Hobbs is President, CEO, & Director of Delcath Systems, Inc. and was previously, President and CEO of AngioDynamics (Nasdaq:ANGO), which he co-founded. Mr. Hobbs is an entrepreneurial senior executive with over 30 years of medical device experience and demonstrated outstanding success in growing profitable medical device businesses. Regarding his new position Mr. Hobbs states, “This is an exciting time for Cappella. Cappella is extremely well-positioned to grow its business and take the pole position in the emerging bifurcation market. I am impressed by the achievements of Cappella’s worldclass development team with Art Rosenthal at its helm and look forward to help transform this new medical practice which is now available to interventional cardiologists and their patients into a commercially highly successful company.”)--
Mr. Hobbs joined Cappella’s Board of Directors early this year and moves now into the Chairman position, previously held by Dr. Wolfgang Oster, MD, PhD, Managing Partner at PolyTechnos Venture-Partners GmbH who will remain a Director. Dr. Oster comments, “I am delighted that Eamonn elevates his presence in the leadership team by assuming the role of Chairman of Cappella. The company has arrived at a juncture which warrants emphasis on commercial objectives and I am certain that Eamonn’s strength and vision will create an eminent position for our technology in the market place.
About Cappella, Inc.
Cappella, Inc. is a medical device company, developing novel solutions for the treatment of complex Coronary Artery Disease (CAD), specifically bifurcation disease. Cappella’s initial product, the Sideguard® Coronary Sidebranch Stent & Delivery System offers interventional cardiologists a straightforward, effective solution that focuses on treating the sidebranch of diseased coronary arteries first, allowing the preferred stent of choice for the main vessel. Optimal self-expanding stent design specific to the anatomy of the sidebranch, combined with the proprietary delivery system provide a dynamic solution for treating sidebranch disease. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For more information, see: www.cappella-med.com.